FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2605317660> ?p ?o ?g. }

• W2605317660 endingPage "18" @default.
• W2605317660 startingPage "12" @default.
• W2605317660 abstract "Background and aims The optimal approaches to management of patients treated with moderate statin doses on lipid parameters are unknown. The ACCENTUATE study aimed to compare the effects of adding the cholesteryl ester transfer protein inhibitor (CETP) evacetrapib, ezetimibe or increasing statin dose in atorvastatin-treated high-vascular risk patients on lipid parameters. Methods 366 patients with atherosclerotic cardiovascular disease (ASCVD) and/or diabetes were treated with atorvastatin 40 mg/day for 28 days prior to randomization to atorvastatin 40 mg plus evacetrapib 130 mg, atorvastatin 80 mg, atorvastatin 40 mg plus ezetimibe 10 mg or atorvastatin 40 mg plus placebo, daily for 90 days at 64 centers in the United States. Lipid parameters, safety and tolerability were measured. Results Addition of evacetrapib significantly reduced LDL-C (−33%) compared with ezetimibe (−27%, p=0.045), increasing statin dose (−6%) and statin alone (0%, p<0.001). Evacetrapib also decreased apoB by 23% compared to 19% with ezetimibe (p=0.06) and 7% with increased statin dose (p<0.001), and reduced Lp(a) by 29% (p<0.001 vs. other groups). Evacetrapib increased HDL-C (+125%), apoA-I (+46%), apoC-III (+50%) and apoE (+28%) (p<0.001 vs. other groups). Non-ABCA1-mediated efflux increased by 53% (p<0.001 vs. other groups) with evacetrapib. ABCA1-mediated efflux also increased by 13% with evacetrapib (p<0.001 vs. ezetimibe, p=0.002 vs. increasing statin dose, and p=0.004 vs. statin alone). Addition of evacetrapib to atorvastatin produced an increase in hsCRP compared with ezetimibe (p=0.02). Conclusions While evacetrapib improved traditional atherogenic and putative protective lipid measures compared with ezetimibe and increasing statin dose in patients with ASCVD and/or diabetes, it also adversely affected novel atherogenic risk factors. These findings may contribute to the lack of clinical benefit observed in the ACCELERATE trial." @default.
• W2605317660 created "2017-04-14" @default.
• W2605317660 creator A5003814092 @default.
• W2605317660 creator A5004434602 @default.
• W2605317660 creator A5007141795 @default.
• W2605317660 creator A5008640203 @default.
• W2605317660 creator A5040589473 @default.
• W2605317660 creator A5052604218 @default.
• W2605317660 creator A5055849986 @default.
• W2605317660 creator A5078824497 @default.
• W2605317660 date "2017-06-01" @default.
• W2605317660 modified "2023-10-14" @default.
• W2605317660 title "Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial" @default.
• W2605317660 cites W1520609538 @default.
• W2605317660 cites W2048760408 @default.
• W2605317660 cites W2090464684 @default.
• W2605317660 cites W2118825330 @default.
• W2605317660 cites W2129750583 @default.
• W2605317660 cites W2137983259 @default.
• W2605317660 cites W2139168645 @default.
• W2605317660 cites W2154043013 @default.
• W2605317660 cites W2155598961 @default.
• W2605317660 cites W2159243445 @default.
• W2605317660 cites W2159449551 @default.
• W2605317660 cites W2247997571 @default.
• W2605317660 cites W2322095705 @default.
• W2605317660 cites W38523360 @default.
• W2605317660 cites W424467158 @default.
• W2605317660 doi "https://doi.org/10.1016/j.atherosclerosis.2017.04.008" @default.
• W2605317660 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28412650" @default.
• W2605317660 hasPublicationYear "2017" @default.
• W2605317660 type Work @default.
• W2605317660 sameAs 2605317660 @default.
• W2605317660 citedByCount "30" @default.
• W2605317660 countsByYear W26053176602017 @default.
• W2605317660 countsByYear W26053176602018 @default.
• W2605317660 countsByYear W26053176602019 @default.
• W2605317660 countsByYear W26053176602020 @default.
• W2605317660 countsByYear W26053176602021 @default.
• W2605317660 countsByYear W26053176602022 @default.
• W2605317660 countsByYear W26053176602023 @default.
• W2605317660 crossrefType "journal-article" @default.
• W2605317660 hasAuthorship W2605317660A5003814092 @default.
• W2605317660 hasAuthorship W2605317660A5004434602 @default.
• W2605317660 hasAuthorship W2605317660A5007141795 @default.
• W2605317660 hasAuthorship W2605317660A5008640203 @default.
• W2605317660 hasAuthorship W2605317660A5040589473 @default.
• W2605317660 hasAuthorship W2605317660A5052604218 @default.
• W2605317660 hasAuthorship W2605317660A5055849986 @default.
• W2605317660 hasAuthorship W2605317660A5078824497 @default.
• W2605317660 hasBestOaLocation W26053176602 @default.
• W2605317660 hasConcept C126322002 @default.
• W2605317660 hasConcept C134018914 @default.
• W2605317660 hasConcept C142724271 @default.
• W2605317660 hasConcept C204787440 @default.
• W2605317660 hasConcept C27081682 @default.
• W2605317660 hasConcept C2776839432 @default.
• W2605317660 hasConcept C2777482532 @default.
• W2605317660 hasConcept C2778096610 @default.
• W2605317660 hasConcept C2778163477 @default.
• W2605317660 hasConcept C2778657065 @default.
• W2605317660 hasConcept C2780072125 @default.
• W2605317660 hasConcept C2780499067 @default.
• W2605317660 hasConcept C45505151 @default.
• W2605317660 hasConcept C555293320 @default.
• W2605317660 hasConcept C71924100 @default.
• W2605317660 hasConcept C98274493 @default.
• W2605317660 hasConceptScore W2605317660C126322002 @default.
• W2605317660 hasConceptScore W2605317660C134018914 @default.
• W2605317660 hasConceptScore W2605317660C142724271 @default.
• W2605317660 hasConceptScore W2605317660C204787440 @default.
• W2605317660 hasConceptScore W2605317660C27081682 @default.
• W2605317660 hasConceptScore W2605317660C2776839432 @default.
• W2605317660 hasConceptScore W2605317660C2777482532 @default.
• W2605317660 hasConceptScore W2605317660C2778096610 @default.
• W2605317660 hasConceptScore W2605317660C2778163477 @default.
• W2605317660 hasConceptScore W2605317660C2778657065 @default.
• W2605317660 hasConceptScore W2605317660C2780072125 @default.
• W2605317660 hasConceptScore W2605317660C2780499067 @default.
• W2605317660 hasConceptScore W2605317660C45505151 @default.
• W2605317660 hasConceptScore W2605317660C555293320 @default.
• W2605317660 hasConceptScore W2605317660C71924100 @default.
• W2605317660 hasConceptScore W2605317660C98274493 @default.
• W2605317660 hasLocation W26053176601 @default.
• W2605317660 hasLocation W26053176602 @default.
• W2605317660 hasLocation W26053176603 @default.
• W2605317660 hasOpenAccess W2605317660 @default.
• W2605317660 hasPrimaryLocation W26053176601 @default.
• W2605317660 hasRelatedWork W1987424073 @default.
• W2605317660 hasRelatedWork W2025076376 @default.
• W2605317660 hasRelatedWork W2498434420 @default.
• W2605317660 hasRelatedWork W2605317660 @default.
• W2605317660 hasRelatedWork W2731104189 @default.
• W2605317660 hasRelatedWork W2883213251 @default.
• W2605317660 hasRelatedWork W2899565173 @default.
• W2605317660 hasRelatedWork W3087468833 @default.
• W2605317660 hasRelatedWork W3168743993 @default.
• W2605317660 hasRelatedWork W4382934914 @default.

• next